Bioproduction of Antibody–Drug Conjugate Payload Precursors by Engineered Cell Factories
Wang, Jie; Xiao, Han; Qian, Zhi-Gang; Zhong, Jian-Jiang
2017-05-01 00:00:00
Antibody–drug conjugates (ADCs), which combine the exquisite specificity of antibodies with the cell-killing ability of cytotoxic drug payloads, have emerged as an attractive means for treating cancers. All (pre)clinical ADCs employ biosynthesized cytotoxins as their ADC payload precursors (APPs). The cost-effective bioproduction of APPs is receiving great interest from both academia and industry. Given the lack of systematic overviews of the topic, we provide the current status of APPs and focus on their state-of-the-art bioproduction strategies, illustrated with typical examples and critical analyses. Challenges in further enhancing the bioproduction efficiency of APPs and other cytotoxins are also discussed. This research has implications for bioprocess and metabolic engineering, systems and synthetic biology, and biopharmaceutical drug discovery, development, and industrialization.
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngTrends in BiotechnologyElsevierhttp://www.deepdyve.com/lp/elsevier/bioproduction-of-antibody-drug-conjugate-payload-precursors-by-5mMNjYMeI0

Abstract

Antibody–drug conjugates (ADCs), which combine the exquisite specificity of antibodies with the cell-killing ability of cytotoxic drug payloads, have emerged as an attractive means for treating cancers. All (pre)clinical ADCs employ biosynthesized cytotoxins as their ADC payload precursors (APPs). The cost-effective bioproduction of APPs is receiving great interest from both academia and industry. Given the lack of systematic overviews of the topic, we provide the current status of APPs and focus on their state-of-the-art bioproduction strategies, illustrated with typical examples and critical analyses. Challenges in further enhancing the bioproduction efficiency of APPs and other cytotoxins are also discussed. This research has implications for bioprocess and metabolic engineering, systems and synthetic biology, and biopharmaceutical drug discovery, development, and industrialization.

Journal

Trends in Biotechnology
– Elsevier

Published: May 1, 2017

Recommended Articles

Loading...

References

Recent advances in the construction of antibody-drug conjugates

Chudasama, V.

Antibody drug conjugates for cancer therapy

Polakis, P.

Antibody–drug conjugates – an emerging class of cancer treatment

Diamantis, N.; Banerji, U.

Expanding the reach of antibody-drug conjugates

Chari, R.V.

Natural product cytotoxins as payloads for antibody drug conjugates

Koehn, F.E.

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

Coupling deep transcriptome analysis with untargeted metabolic profiling in Ophiorrhiza pumila to further the understanding of the biosynthesis of the anti-cancer alkaloid camptothecin and anthraquinones